BioWorld

May 27, 2009

View Archived Issues

MAP Gets Boost on Positive Phase III Migraine Study

Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today) Read More

Cytokinetics' Cardio Bet Pays Off with Amgen Option Exercise

Read More

Cancer, Depression Have Direct Link in Cytokines, Corticosterone

Read More

United Therapeutics Jumps on Adcirca Approval in PAH

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More

Appointments And Advancements

Read More